• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Elixir Medical unveils ‘bioadaptive’ metallic drug-eluting stent at TCT 2017

October 31, 2017 By Sarah Faulkner

Elixir Medical DynamXInterventional cardiologists have used stents to keep the heart’s coronary arteries open for decades. Transitioning from bare-metal stents to drug-eluting stents in the early 2000s brought tremendous benefits for patients.

“But over the last 10 years, the technological progress and meaningful clinical improvements have plateaued,” Elixir Medical CEO Motasim Sirhan told Drug Delivery Business News.

“When you stent an artery today, you actually cage it and by caging it you are inhibiting the normal pulsatility of the artery and inhibiting its built-in mechanism of adaptive remodeling intended to slow disease progression and clinical events,” he explained.

So Sirhan’s 65-person company set out to create a device that has the therapeutic benefit of a drug-eluting stent, but also helps the vessel resume its natural healing process. And last night at the annual Transcatheter Cardiovascular Therapeutics meeting, Elixir Medical unveiled what the company is touting as a new class of drug-eluting stents.

The company’s DynamX device is a 71-microns thin cobalt-chromium drug-eluting stent with a biodegradable polymer coating that releases novolimus. Segments of the stent are held together by the polymer coating, which is designed to absorb in six months.

“After you open a diseased vessel and allow it to heal, you want a stent to uncage and conform to the vessel anatomy letting nature take over now that the vessel is open and healed, thereby continuing to reduce inflammation and irritation to the vessel wall. DynamX is uniquely designed to uncage and conform to the vessel anatomy,” Sirhan said.

The chief executive explained that when plaque builds up in an artery over time, the artery will naturally expand to compensate in a phenomenon known as adaptive remodeling. Metallic stents stop the artery from doing this, which could potentially accelerate disease progression in the process, Sirhan said.

But Elixir’s DynamX drug-eluting stent, as well as the company’s DESolve bioresorbable scaffold, is designed to help the vessel resume adaptive remodeling.

“When developing DynamX, we matched the acute performance of a DES, and then we configured DynamX to uncage at 6 months restoring the vessel normal pulsatility and adaptive remodeling, and it’s normal geometric configuration,” Sirhan said. “We successfully developed DESolve, the only BRS to demonstrate adaptive remodeling at 6 months. We are confident DynamX DES will demonstrate similar results in the clinic.”

The company plans to bring its DynamX device to the clinic soon, enrolling up to 50 patients in its first study.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Stents, Vascular Tagged With: Elixir Medical Corporation

IN CASE YOU MISSED IT

  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS